

# Numira Biosciences

**Contact:** Michael Beeuwsaert  
President & CEO  
Numira Biosciences Inc.  
(949) 623-8603  
mbeeuwsaert@numirabio.com

**Joint study by DOW, Pfizer, and CCRI utilizing Virtual Histology™ featured in the June 2007 Issue of Birth Defects Research Part B**

IRVINE, Calif., July 11, 2007 – Numira Biosciences Inc., a leader in small animal imaging, announced today that a joint study by DOW Chemical, Pfizer, and Children’s Cancer Research Institute of San Antonio titled “Refinement of a Morphological Scoring System for Postimplantation Rabbit Conceptuses,” is featured in the June issue of Birth Defects Research Part B. The study, which indicates that whole embryo culture systems support normal morphological development of rabbit conceptuses was aided by means of microCT- based Virtual Histology™.

Virtual Histology™ provides a novel means of rapid, non-destructive and cost-effective high-resolution phenotypic evaluation of developing embryos and fetuses. Numira’s proprietary imaging reagent is differentially absorbed by the various soft tissues, resulting in exquisite 2D and 3D data sets which are ideally suited to segmentation and quantitative assessment.

## About Numira Biosciences

Numira Biosciences is a specialty R&D tools company focused on leveraging advances in genetics and molecular imaging to create a catalog of novel, high-value products that provide researchers with unprecedented insight into genomics, developmental biology, mechanisms of disease, drug efficacy, and toxicity.

For more information, please visit the company’s website at [www.numirabio.com](http://www.numirabio.com).

###